Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

SAN DIEGO, Feb. 8, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2012.

For the fourth quarter of 2012, the Company reported net income of $9.5 million, or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011. For the year ended December 31, 2012, the Company reported net income of $5.0 million, or $0.08 per fully diluted share, as compared to net income of $37.6 million, or $0.67 per fully diluted share, for 2011. One-time milestone payments of $30.0 million during 2011 were primarily responsible for the change in operating results year over year.

The Company's balance sheet at December 31, 2012 reflected total assets of $196.0 million, including cash, investments and receivables of $188.3 million compared with balances at December 31, 2011 of $138.4 million and $131.7 million, respectively.  During January 2012, the Company completed a public offering of approximately 10.9 million shares of common stock that resulted in net proceeds of approximately $83.0 million.

"During 2012 we continued to perform to financial plan and were successful in moving our VMAT2 tardive dyskinesia program forward, as well as AbbVie advancing the elagolix endometriosis and uterine fibroids programs," said Kevin C. Gorman, President and CEO of Neurocrine Biosciences. "Looking to 2013 we will have two Phase IIb readouts for our VMAT2 program, expect AbbVie to progress elagolix into Phase IIb in uterine fibroids, and we anticipate one additional program entering the clinic, resulting in a very productive year."

Revenues for the fourth quarter of 2012 were $21.9 million, compared to $11.1 million for the same period in 2011. The $10.8 million increase in revenue is primarily due to higher rev
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the ... testing methodologies relating to cannabis, today announced that it ... credit from an existing stockholder of the Company. ... commitment from one of our existing stockholders,” stated ... will help accelerate our planned expansions into the Connecticut ...
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
(Date:11/21/2014)... CA (PRWEB) November 20, 2014 Offering ... their Sartorius Entris Balance promotion . The Sartorius ... seeking a durable, high accuracy, and easy-to-maintain balance entry ... in Germany. It was designed to help customer’s bridge ... and a balance that is very durable. Sartorius is ...
(Date:11/21/2014)... BlueInGreen, LLC ( BlueInGreen® ) and ... PCI, Inc., leading suppliers of ozone process technology ... to provide a new state-of-the-art ozone system for ... Wastewater Treatment. The new ozone disinfection system ... dissolution technology, Pinnacle Ozone’s industry leading Zenith™ ozone ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Viruses' Advantage of Surprise is Lost 2Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4
... May 18 ViroPharma Incorporated (Nasdaq: VPHM ... National Organization for Rare Disorders (NORD) Annual Gala for ... to market for a rare and devastating disorder -- ... genetic disorder caused by a deficiency of C1 inhibitor, ...
... Debt Facility; Support Profitable GrowthALISO VIEJO, Calif., May 18 ... CLRT ), a premier anatomic pathology and molecular ... industry, announced today that it has completed the second ... with Oak Investment Partners , a ...
... and Merieux Alliance,have signed a letter of intent for ... The Institut Pasteur and Merieux Alliance (which comprises the ... to,pool their resources and efforts to fight infectious diseases ... - Clinical diagnostics and theranostics (in ...
Cached Biology Technology:ViroPharma Incorporated Honored by the National Organization for Rare Disorders 2ViroPharma Incorporated Honored by the National Organization for Rare Disorders 3ViroPharma Incorporated Honored by the National Organization for Rare Disorders 4ViroPharma Incorporated Honored by the National Organization for Rare Disorders 5Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 2Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 3Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 4Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 5Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners 6The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases 2The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases 3
(Date:11/5/2014)... diversity in their ability to identify scents and odors. ... their perceptual evaluation of odors, with women outperforming men ... Sex differences in olfactory detection may play a role ... one,s perception of smell, which is naturally linked to ... been suggested to be cognitive or emotional, rather than ...
(Date:11/4/2014)... the right amount of death at the right time ... to new research that could help in understanding animal ... , In a paper in the journal Trends ... and European colleagues conclude that the kind of positive ... of individuals, or mortality, depends on the size and ...
(Date:11/4/2014)... GABLES, Fla. (November 4, 2014) — Think about the ... ask: How do neighboring cells know that they are ... and how do these tissues find the correct place ... are answering these crucial questions. , In a new ... use to communicate with their surrounding neighbors, at the ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2
... Larry Murdoch have received an $891,000 Environmental Protection Agency ... in geological formations located deep below the earth,s surface. ... believed to be the leading cause of global warming, ... most promising alternatives for reducing emissions using current technology. ...
... . The DFG has approved the establishment of ... decision was made recently by the relevant Grants Committee in Bonn. ... a total of 132 million. In addition, 20 percent overhead funding ... centres, research topics range from modern prostheses to political reforms to ...
... Journal of Experimental Biology are pleased to announce ... Scientifique (CNRS) in the Universit de Nice-Sophia-Antipolis is the winner ... prize is awarded in recognition of an outstanding achievement and ... JEB Editor-in-Chief, and adds that ,we truly appreciate ...
Cached Biology News:DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4
... serum is collected from fasted Rhesus monkeys of ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
Porcine Serum US Origin 6 Months or Older...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
... is collected off the clot from fasted Cynomolgus monkeys ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA N-11: ...
Biology Products: